Please note that the application must be completed in one session - it can not be saved. The application form can be accessed from a link at the bottom of this page. Applications in which more than 30% of the total budget is allocated for the payment of personnel and/or salaries will not be accepted.Īll applications must be made on-line through the AHCDO web site. Preference will be given to those applications which do not include a request for funding to support personnel and/or salaries. The fund is designed to promote and foster research and clinical excellence in bleeding disorders and is intended to encourage and support researchers and clinicians in the bleeding disorders field. The next application round is planned for March 2023. Radha has an interest in bleeding disorders and molecular pathology and seeks to broaden our understanding of these fields through research funded by AHCDO.
Radha is also the current AHCDO Research Fellow. It will also broaden our understanding of the genotype-phenotype correlation present within this disorder and guide whether molecular typing at diagnosis may help us better characterise the clinical phenotype, navigate future treatment decisions, particularly regarding prophylaxis, and ascribe inheritance risk in this complex cohort of patients.ĭr Radha Ramanan is a Haematology Fellow at Alfred Health and is also undertaking a PhD at Monash University, having completed her advanced training in clinical and laboratory haematology in 2021 at Alfred Health. The results obtained will inform how successful current therapeutic approaches are in the prevention of bleeding/thrombotic events. Significance: This projects aims to provide an analysis of real-world data concerning the CFD cohort across Australia. We will assess types of treatment these patients have received in these different settings. We will also record the types of bleeding or clotting problems these patients have experienced over their lifetime, and if any of those problems arose during pregnancy or surgeries. This project will look closely at the types of gene mutations seen in various patients with a fibrinogen disorder by genetic testing.
#THE TRIAL SUMMARY JOHN LLOYD CODE#
Genes are the genetic material which code for all the proteins in the body, including the fibrinogen clotting factor. Some of this difference may relate to the various gene mutations that can be seen with this condition.
Given the rarity of this disorder, we are still trying to understand out why some patients behave differently to others. This disorder causes different problems in different patients, for example, one person may experience blood clots while another may have problems with bleeding, while someone else again may have no noticeable problems at all. These disorders are inherited which means these patients are born with the problem. The AHCDO Executive Committee are pleased to announce that the successful application for 2022 isĭr Radha Ramanan for the project titled ‘Phenotypic characterisation and molecular profiling of congenital fibrinogen disorders: the Australian experience’.Ĭongenital fibrinogen disorders are rare disorders affecting of one of the major clotting proteins of the blood, fibrinogen.
#THE TRIAL SUMMARY JOHN LLOYD HOW TO#
How to access deidentified data from the ABDR for research purposes.
0 kommentar(er)
